| Dermatitis, Atopic
Eucrisa vs Opzelura
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Eucrisa vs Opzelura with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOpzelura has a higher rate of injection site reactions vs Eucrisa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Opzelura but not Eucrisa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eucrisa
Opzelura
At A Glance
Topical
Twice daily
PDE-4 inhibitor
Topical
Twice daily
JAK inhibitor
Indications
- Dermatitis, Atopic
- Dermatitis, Atopic
- Vitiligo
Dosing
Dermatitis, Atopic Apply a thin layer twice daily to affected areas; once clinical effect is achieved, consider reducing to once daily. For topical use only.
Dermatitis, Atopic Apply a thin layer topically twice daily to affected areas of up to 20% body surface area; do not use with occlusive dressings; adults and pediatric patients 12 years and older: max one 60 gram tube per week or one 100 gram tube per 2 weeks; pediatric patients 2 to 11 years: max one 60 gram tube per 2 weeks.
Vitiligo Apply a thin layer topically twice daily to affected areas of up to 10% body surface area; max one 60 gram tube per week or one 100 gram tube per 2 weeks.
Contraindications
- Known hypersensitivity to crisaborole or any component of the formulation
—
Adverse Reactions
Most common (>=1%) Application site pain
Postmarketing Allergic contact dermatitis
Most common (>=1%) - Atopic Dermatitis nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea, upper respiratory tract infection, COVID-19, application site reactions, pyrexia, white blood cell decreased
Most common (>=1%) - Nonsegmental Vitiligo application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia
Pharmacology
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor; PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels, though the specific mechanism by which it treats atopic dermatitis is not well defined.
Ruxolitinib is a JAK inhibitor that inhibits JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function; JAK signaling involves STAT recruitment to cytokine receptors, activation, and nuclear localization leading to modulation of gene expression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eucrisa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (10/12) · Qty limit (9/12)
Opzelura
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Eucrisa
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (4/8) · Qty limit (5/8)
Opzelura
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Eucrisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Opzelura
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eucrisa.
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EucrisaView full Eucrisa profile
OpzeluraView full Opzelura profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.